Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | MedNEXT Journal of Medical and Health Sciences |
Texto Completo: | https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/194 |
Resumo: | Introduction: In the scenario of implantology and osteoporosis, it is highlighted that the high need and use of treatments related to dental implants result from the combined effect of several factors, highlighting aging and bone fragility. In this context, osteoporosis is a global bone disease prevalent in human aging. Bisphosphonates (BPs) are commonly used as therapy because they influence hard and soft tissue calcium metabolism. Objective: It was to present the main considerations and scientific evidence of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis, as well as to emphasize the harm caused by the occurrence of osteonecrosis. Methods: The rules of the Systematic Review-PRISMA Platform were followed. The research was carried out from February 2022 to May 2022 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 110 articles were found. In total, 58 articles were fully evaluated and 28 were included and evaluated in this study. Of the initial total of articles, 26 articles were excluded because they did not meet the GRADE classification, and 4 were excluded because they presented a risk of bias. It was concluded that osteoporosis is a metabolic condition that affects alveolar bone density, which may compromise the dental implant process. Therefore, the careful use of bisphosphonates is necessary for the osseointegration process, however, dental surgeons are encouraged to know the diagnosis so that they can make a careful assessment, observing the quality of the bone through routine imaging exams, to prevent osteonecrosis. In addition, alendronate sodium is used to decrease bone resorption, being an adjuvant therapeutic agent for the treatment of osteoporosis. |
id |
FACERES-1_2fa4ca7136c73cfc89e111e3aed62a4e |
---|---|
oai_identifier_str |
oai:ojs2.mednext.zotarellifilhoscientificworks.com:article/194 |
network_acronym_str |
FACERES-1 |
network_name_str |
MedNEXT Journal of Medical and Health Sciences |
repository_id_str |
|
spelling |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic reviewDental implantsOsteoporosisBisphosphonateOsseointegrationOsteonecrosisIntroduction: In the scenario of implantology and osteoporosis, it is highlighted that the high need and use of treatments related to dental implants result from the combined effect of several factors, highlighting aging and bone fragility. In this context, osteoporosis is a global bone disease prevalent in human aging. Bisphosphonates (BPs) are commonly used as therapy because they influence hard and soft tissue calcium metabolism. Objective: It was to present the main considerations and scientific evidence of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis, as well as to emphasize the harm caused by the occurrence of osteonecrosis. Methods: The rules of the Systematic Review-PRISMA Platform were followed. The research was carried out from February 2022 to May 2022 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 110 articles were found. In total, 58 articles were fully evaluated and 28 were included and evaluated in this study. Of the initial total of articles, 26 articles were excluded because they did not meet the GRADE classification, and 4 were excluded because they presented a risk of bias. It was concluded that osteoporosis is a metabolic condition that affects alveolar bone density, which may compromise the dental implant process. Therefore, the careful use of bisphosphonates is necessary for the osseointegration process, however, dental surgeons are encouraged to know the diagnosis so that they can make a careful assessment, observing the quality of the bone through routine imaging exams, to prevent osteonecrosis. In addition, alendronate sodium is used to decrease bone resorption, being an adjuvant therapeutic agent for the treatment of osteoporosis.Faceres2022-07-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/19410.54448/mdnt22S404MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. S4 (2022): MedNEXT - Supplement 4 - July 2022MedNEXT Journal of Medical and Health Sciences; v. 3 n. S4 (2022): MedNEXT - Supplement 4 - July 20222763-567810.54448/mdnt22S4reponame:MedNEXT Journal of Medical and Health Sciencesinstname:Faculdade de Medicina em São José do Rio Preto (Faceres)instacron:FACERESenghttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/194/185Copyright (c) 2022 MedNEXT Journal of Medical and Health Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessOrtega, Liliane Fernanda LuzCicareli, Alvaro JoséKassis, Elias Naim2022-07-12T21:45:22Zoai:ojs2.mednext.zotarellifilhoscientificworks.com:article/194Revistahttps://mednext.zotarellifilhoscientificworks.com/index.php/mednextPUBhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/oaimednextjmhs@zotarellifilhoscientificworks.com2763-56782763-5678opendoar:2022-07-12T21:45:22MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres)false |
dc.title.none.fl_str_mv |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
title |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
spellingShingle |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review Ortega, Liliane Fernanda Luz Dental implants Osteoporosis Bisphosphonate Osseointegration Osteonecrosis |
title_short |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
title_full |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
title_fullStr |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
title_full_unstemmed |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
title_sort |
Benefits and harmfulness of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis: a concise systematic review |
author |
Ortega, Liliane Fernanda Luz |
author_facet |
Ortega, Liliane Fernanda Luz Cicareli, Alvaro José Kassis, Elias Naim |
author_role |
author |
author2 |
Cicareli, Alvaro José Kassis, Elias Naim |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Ortega, Liliane Fernanda Luz Cicareli, Alvaro José Kassis, Elias Naim |
dc.subject.por.fl_str_mv |
Dental implants Osteoporosis Bisphosphonate Osseointegration Osteonecrosis |
topic |
Dental implants Osteoporosis Bisphosphonate Osseointegration Osteonecrosis |
description |
Introduction: In the scenario of implantology and osteoporosis, it is highlighted that the high need and use of treatments related to dental implants result from the combined effect of several factors, highlighting aging and bone fragility. In this context, osteoporosis is a global bone disease prevalent in human aging. Bisphosphonates (BPs) are commonly used as therapy because they influence hard and soft tissue calcium metabolism. Objective: It was to present the main considerations and scientific evidence of the use of bisphosphonate in the osseointegration process for dental implants in patients with osteoporosis, as well as to emphasize the harm caused by the occurrence of osteonecrosis. Methods: The rules of the Systematic Review-PRISMA Platform were followed. The research was carried out from February 2022 to May 2022 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 110 articles were found. In total, 58 articles were fully evaluated and 28 were included and evaluated in this study. Of the initial total of articles, 26 articles were excluded because they did not meet the GRADE classification, and 4 were excluded because they presented a risk of bias. It was concluded that osteoporosis is a metabolic condition that affects alveolar bone density, which may compromise the dental implant process. Therefore, the careful use of bisphosphonates is necessary for the osseointegration process, however, dental surgeons are encouraged to know the diagnosis so that they can make a careful assessment, observing the quality of the bone through routine imaging exams, to prevent osteonecrosis. In addition, alendronate sodium is used to decrease bone resorption, being an adjuvant therapeutic agent for the treatment of osteoporosis. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/other |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/194 10.54448/mdnt22S404 |
url |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/194 |
identifier_str_mv |
10.54448/mdnt22S404 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/194/185 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Faceres |
publisher.none.fl_str_mv |
Faceres |
dc.source.none.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. S4 (2022): MedNEXT - Supplement 4 - July 2022 MedNEXT Journal of Medical and Health Sciences; v. 3 n. S4 (2022): MedNEXT - Supplement 4 - July 2022 2763-5678 10.54448/mdnt22S4 reponame:MedNEXT Journal of Medical and Health Sciences instname:Faculdade de Medicina em São José do Rio Preto (Faceres) instacron:FACERES |
instname_str |
Faculdade de Medicina em São José do Rio Preto (Faceres) |
instacron_str |
FACERES |
institution |
FACERES |
reponame_str |
MedNEXT Journal of Medical and Health Sciences |
collection |
MedNEXT Journal of Medical and Health Sciences |
repository.name.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres) |
repository.mail.fl_str_mv |
mednextjmhs@zotarellifilhoscientificworks.com |
_version_ |
1796798220039356416 |